App-Quantinova.ai

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Imlygic

Correlation of indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma with Breslow thickness and peritumoral inflammation.

Dagmar von Bubnoff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Circulating tumor DNA (ctDNA) to track responses and to capture the genomic heterogeneity of metastatic melanoma.

Shahneen Kaur Sandhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.

Robyn Saw - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Dabrafenib Mesylate

An app to increase cross-referral and recruitment to melanoma clinical trials.

Maria Gonzalez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy.

Heidi D. Klepin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Randomised controlled trial of a psycho-educational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma.

Anne E. Cust - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Depression

N/A

A culturally adapted, multidisciplinary psychoeducation program for early-stage breast cancer survivors in Asia: A randomized, controlled trial.

Alexandre Chan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Methadone hydrochloride

Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI.

Janette L. Vardy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.

David Christopher Currow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Anamorelin

Toxicity and outcome of anti-GD2 Antibody ch14.18/CHO in Front-Line High-Risk Neuroblastoma Patients: Final Results of the Phase III Immunotherapy Randomization (HR-NBL1/SIOPEN Trial).

Ruth Ladenstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

ch14.18

SIOPEL 6: A multi-centre open label randomized phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma.

Penelope Rachel Brock - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

sodium thiosulfate

Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrens Oncology Group (COG).

Steven G. DuBois - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

MIBG

Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Ruth Ladenstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Melphalan

18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Childrens Oncology Group (COG).

Douglas James Harrison - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Soft tissue sarcoma

Methadone hydrochloride

Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.

Jeremy Howard Lewin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of biglycan on melanoma invasiveness via increased tissue stiffness and integrin-1 expression.

Hana Andrlova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.

Mustafa Khasraw - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Protein-bound paclitaxel

Targeted intraoperative radiotherapy tumour bed boost during breast conserving surgery after neoadjuvant chemotherapy.

Hans-Christian Kolberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.

Ben Tran - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

13968 Abstracts